It is true that most of us cannot to pay for a house upfront & have to get a mortgage from a bank, however,easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
i>
There are cases whereby people take up a huge bank loan to purchase condominiums & terrace houses when their income range is nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
just 1 to 2 k.
Their bank loan usually involves a high interest rates & long repayment period.The longer the repayand physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ment period, the more interest you pay.
Buying a car - Your car is not your asset if you get a car
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
oan to pay for it.
It is considered a liability because the car loan drains away money from you every month on top of gas, ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
road tax & car park charges.
In fact, the bank owes your car, not you.It is a negative cash generating asset.dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Gambling in the stock market - Most people buy shares of a company based on its price alone.
- Th
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ey are essentially chasing after the stock price or timing the market, hoping that the price of the shares they brought will go up
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
& they will make a quick kill.
They buy based on hot tips, friend or broker’s recommendations or adopting a ‘herd mentalityt?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
’ instead of fundamentally studying the business which the shares represent to evaluate whether the company is a good investment.
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
i>
Buying derivatives like warrants, options & futures that is highly unpredictable & use excessive leverage without having a goy and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
od understanding of how it works & the associated risks
Borrowing money from loan sharks .
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
worse than borrowing money from the bank
Loan sharks provide an extra service of physically abusing you if you cannot meet elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
your debt obligations
This will lead to an extra hospitalization & medical costs.
Yours Sincerely
Chen Mingzh
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products